Specialty Pharmacy

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

Sofosbuvir-based regimens for the treatment of hepatitis C were well tolerated in Asian American communities, according to a new study.

A small mid-stage study demonstrated promising results for gene therapy candidate AMT-061 in patients with severe hemophilia B.

The trial evaluated margetuximab compared with trastuzumab, in combination with chemotherapy, for the treatment of HER 2-positive breast cancer.

Top news of the day across the health care landscape.

African Americans are disproportionately affected by HIV infection in the United States.

Those with hepatitis B virus have a significantly elevated risk for developing any type of age-related macular degeneration, according to a new report

A new FDA program aims to facilitate better quality drug manufacturing through recognized consensus standards.

Phase 3 trial evaluating isatuximab in combination with standard of care met the primary endpoint of prolonging progression-free survival.

If approved, apalutamide (Erleada) plus androgen deprivation therapy would offer an additional treatment option for patients with metastatic castration-sensitive prostate cancer.

Top news of the day across the health care landscape.

The FDA announced approval of Wixela Inhub on January 30, 2019.

Biologic therapy used to treat severe psoriasis found to improve coronary artery plaque burden.

The new approval allows for daratumumab (Darzalex) to be administered as a split infusion over 2 consecutive days.

Zogenix is seeking approval for its low-dose fenfluramine therapy, ZX008 (Fintepla), for the treatment of seizures associated with Dravet syndrome.

Top news of the day across the health care landscape.

Sephin1 found to protect oligodendrocytes, axons, and myelin, as well as reduce central nervous system inflammation in multiple sclerosis.

The economics of one and done gene therapies dictate a revenue model that requires outcomes-based risk.

The supplemental Biologics License Application was filed based on positive overall survival data from a phase 3 clinical trial for pembrolizumab in the treatment of recurrent or metastatic head and neck squamous cell carcinoma.

There are currently no FDA-approved therapies for the prevention or treatment of acute graft-versus-host disease.

Immunotherapy may become a viable option for patients with cancer infected with HIV.

Top news of the day across the health care landscape.

Robert F. Sidonio Jr, MD, assistant professor of pediatrics at Emory University, Children's Healthcare of Atlanta, discusses how a multi-disciplinary clinic model improves patient care in hemophilia treatment centers.

Analysis finds universal screening for hepatitis C virus infection would be cost effective and provide greater benefit than the currently recommended birth cohort screening.

The study is the longest observation to date of patients with advanced Merkel cell carcinoma receiving first-line pembrolizumab.

A recent model by Massachusetts General Hospital projects that without proper policy, public health and health care delivery efforts, the opioid overdose epidemic will increase.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

Top news of the day across the health care landscape.